AptaBio Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	2,055	323.87	48.35
Revenue Growth (YoY)	4150.33%	569.80%	-
Cost of Revenue	1,899	262.8	11.15
Gross Profit	156.29	61.06	37.21
Selling, General & Admin	3,893	3,385	2,788
Research & Development	12,253	12,380	6,197
Other Operating Expenses	107.47	130.03	74.48
Operating Expenses	17,819	16,965	9,544
Operating Income	-17,663	-16,904	-9,507
Interest Expense	-3,051	-1,183	-4.49
Interest & Investment Income	2,515	1,984	1,572
Earnings From Equity Investments	-300.78	-4.19	-
Currency Exchange Gain (Loss)	14.69	-29.52	-14.43
Other Non Operating Income (Expenses)	49	1,688	42.49
EBT Excluding Unusual Items	-18,435	-14,448	-7,911
Gain (Loss) on Sale of Investments	-635.16	-244.29	-2,654
Pretax Income	-19,071	-14,692	-10,565
Income Tax Expense	-2,630	-2,630	-
Net Income	-16,440	-12,062	-10,565
Preferred Dividends & Other Adjustments	-1,173	-195.14	-
Net Income to Common	-15,267	-11,867	-10,565
Shares Outstanding (Basic)	22	22	22
Shares Outstanding (Diluted)	22	22	22
Shares Change (YoY)	0.05%	0.05%	-
EPS (Basic)	-684.66	-532.16	-474.00
EPS (Diluted)	-684.66	-532.16	-474.00
Free Cash Flow	-17,003	-15,440	-7,874
Free Cash Flow Per Share	-762.50	-692.42	-353.27
Gross Margin	7.60%	18.85%	76.95%
Operating Margin	-859.43%	-5219.25%	-19661.23%
Profit Margin	-742.87%	-3663.98%	-21849.26%
Free Cash Flow Margin	-827.33%	-4767.39%	-16284.04%
EBITDA	-17,123	-16,364	-9,022
D&A For EBITDA	539.93	539.11	484.62
EBIT	-17,663	-16,904	-9,507
Advertising Expenses	-	3	7.07

Source: S&P Capital IQ. Standard template. Financial Sources.